New Blood Test Promises 90% Accuracy in Alzheimer’s Diagnosis
Scientists have achieved a major breakthrough in Alzheimer’s disease diagnosis with the development of a blood test that can identify the condition with approximately 90% accuracy. The test, known as PrecivityAD2, measures the ratio of multiple key biomarkers of Alzheimer’s disease directly from blood samples, potentially revolutionizing early detection methods.
Currently, accurate Alzheimer’s diagnosis requires either cerebrospinal fluid samples or expensive PET brain scans. This new blood test could dramatically expand access to testing and speed up diagnosis, allowing patients to begin treatment earlier when interventions may be more effective.
The breakthrough represents a significant advancement in the fight against Alzheimer’s, which affects approximately seven million people in Europe alone. While the FDA has not yet approved the test and it’s not covered by insurance, experts believe it could transform how the disease is detected and managed in clinical settings.
- Key Takeaways:
- The new blood test, PrecivityAD2, can identify Alzheimer’s with about 90% accuracy.
- This test could revolutionize early detection methods, expanding access to testing and speeding up diagnosis.
- While not yet FDA approved or covered by insurance, experts believe this test could transform Alzheimer’s detection and management.
Source: National Geographic